Lipoprotein (a) Distribution in Aortic Stenosis Patients
In this cross-sectional series of unselected AS patients followed in a valve clinic, only 1 in every 4 patients had a significantly elevated Lp(a) level. Novel Lp(a)-lowering therapies may have limited applicability to most patients with AS and highlight the need for further research into understanding the pathophysiology of AS and developing medical therapies targeting different pathways.
Authors
- Andrew Mulloy
- Vincent Chan (ORCID: https://orcid.org/0000-0002-1795-4826)
- Dimitri Arangalage (ORCID: https://orcid.org/0000-0002-0898-9090)
- Hassan Alfraidi (ORCID: https://orcid.org/0000-0002-9826-9184)
- Michael-Roy R Durr
- Graeme Prosperi‐Porta (ORCID: https://orcid.org/0000-0003-3356-5262)
- Alwaleed Aljamaan
- David Messika‐Zeitoun (ORCID: https://orcid.org/0000-0002-6278-5670)
- Ian G. Burwash (ORCID: https://orcid.org/0000-0003-1083-2284)
- Moiz Lakhani (ORCID: https://orcid.org/0009-0009-4603-826X)
- Luc Beauchesne (ORCID: https://orcid.org/0000-0003-4288-1945)
- Lawrence Lau (ORCID: https://orcid.org/0009-0003-0184-4416)
- Roja Gauda
- Thierry Mesana
- Anahita Tavosi
Institutions
- University of Ottawa (CA)
- Ottawa Hospital (CA)
- Assistance Publique – Hôpitaux de Paris (FR)
Publication Details
- Journal
- JACC Advances
- Published
- 2025-03-22
- DOI
- https://doi.org/10.1016/j.jacadv.2025.101662
- Citations
- 2
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 4.01
Funders
- University of Ottawa Heart Institute Foundation